Tiludronic acid

Generic Medicine Info
Indications and Dosage
Paget's disease of bone
Adult: >18 yr: 400 mg once daily for 3 mth, repeat if needed after an interval of at least 3-6 mth.
Renal Impairment
CrCl (mL/min) Dosage
<30 Not recommended.
Severe renal impairment; pregnancy.
Special Precautions
Acute upper GI inflammation. Take with plenty of water, at least 2 hr before or after meals.
Adverse Reactions
Dysphagia, nausea, vomiting, diarrhoea or constipation, asthenia, dizziness, headache, skin reactions, hypocalcaemia, hypophosphataemia, musculoskeletal pain, osteonecrosis of the jaw, ocular disturbances, oesophagitis, oesophageal and gastric ulcer.
Hypocalcaemia, acute renal failure. Treatment is supportive and symptomatic. Milk or antacids may be given to minimise absorption for oral overdosage. Dialysis unlikely to be helpful.
Drug Interactions
Bioavailability increased by indometacin when taken at same time. Increased risk of hypocalcaemia with aminoglycosides. Decreased bioavailability when aspirin taken 2 hr after tiludronic acid. Absorption reduced by antacids, calcium salts, magnesium-containing laxatives and iron.
Food Interaction
Avoid food (particularly calcium-containing products) for 2 hr before and after tiludronic acid.
Description: Tiludronic acid inhibits bone resorption. It also prevents formation and dissolution of hydroxyapatite crystals, therefore may interfere with bone mineralisation.
Absorption: Poorly absorbed from GI tract. Oral bioavailability: 6% (fasting).
Distribution: Protein-binding: 90%, mostly to albumin.
Metabolism: Not metabolised.
Excretion: Half excreted in urine; remainder sequestered to bone.
Store at 15-30°C (59-86°F).
MIMS Class
Agents Affecting Bone Metabolism
Disclaimer: This information is independently developed by MIMS based on Tiludronic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in